Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Does Estimated Pulse Wave Velocity Add Prognostic Information? MORGAM Prospective Cohort Project

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Risk of Developing Hypokalemia in Patients With Hypertension Treated With Combination Antihypertensive Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Level of Physical Activity, Left Ventricular Mass, Hypertension, and Prognosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association Between Prescribed Ibuprofen and Severe COVID-19 Infection: A Nationwide Register-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Richard B Devereux
  • Casper N Bang
  • Mary J Roman
  • Vittorio Palmieri
  • Kurt Boman
  • Eva Gerdts
  • Markku S Nieminen
  • Vasilios Papademetriou
  • Kristian Wachtell
  • Darcy A Hille
  • Björn Dahlöf
Vis graf over relationer

In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular mass×wall stress×heart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate in Cox models assessing predictors of the LIFE primary composite end point (cardiovascular death, MI, or stroke), its individual components, and all-cause mortality. At baseline, the triple product in both treatment groups was, compared with normal adults, elevated in 70% of patients. During randomized treatment, the triple product was reduced more by atenolol, with prevalences of elevated triple product of 39% versus 51% on losartan (both P≤0.001). In Cox regression analyses adjusting for age, smoking, diabetes mellitus, and prior stroke, MI, and heart failure, 1 SD lower triple product was associated with 23% (95% confidence interval 13%-32%) fewer composite end points, 31% (18%-41%) less cardiovascular mortality, 30% (15%-41%) lower MI, and 22% (11%-33%) lower all-cause mortality (all P≤0.001), without association with stroke (P=0.34). Although losartan-based therapy reduced ventricular mass more, greater heart rate reduction with atenolol resulted in larger reduction of the triple product. Lower triple product during antihypertensive treatment was strongly, independently associated with lower rates of the LIFE primary composite end point, cardiovascular death, and MI, but not stroke.

OriginalsprogEngelsk
TidsskriftHypertension
Vol/bind66
Udgave nummer5
Sider (fra-til)945-53
Antal sider9
ISSN0194-911X
DOI
StatusUdgivet - 2015

ID: 45940906